Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

This study is testing the combination of tislelizumab (an immunotherapy drug) with targeted radiation therapy (SBRT) given before surgery in patients with advanced head and neck squamous cell carcinoma — cancer of the throat, mouth, or nearby structures that has not yet spread distantly. **You may be eligible if...** - You have a confirmed diagnosis of squamous cell carcinoma of the head and neck (stage III–IVB) - Your tumor is considered surgically removable or borderline resectable by a multidisciplinary team - Your cancer is NOT HPV-positive oropharyngeal cancer - You are between 18 and 70 years old with adequate organ function - Your general health score (Karnofsky) is 70 or above **You may NOT be eligible if...** - You have previously received chemotherapy or head and neck surgery (beyond diagnostic biopsies) - Your cancer has spread to distant organs - You have significant autoimmune conditions or are on immunosuppressive therapy Talk to your doctor to see if this trial is right for you.